Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
Portfolio Pulse from
Accuray Incorporated has received approval from the Chinese National Medical Products Administration for its Radixact SynC and CyberKnife S7 systems, expanding its product portfolio in China.
January 13, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Accuray has received approval from China's NMPA for its Radixact SynC and CyberKnife S7 systems, which could enhance its market presence and sales in China.
The approval of Radixact SynC and CyberKnife S7 systems by the Chinese NMPA is a significant regulatory milestone for Accuray, potentially increasing its market share and sales in China. This development is likely to positively impact Accuray's stock price in the short term as it expands its product offerings in a major market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100